Relmada Therapeutics, Inc. (RLMD)

Market Cap	455.40M +5,814.3%
Revenue (ttm)	n/a
Net Income	-56.17M
EPS	-1.77
Shares Out	73.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,457,655
Open	6.45
Previous Close	6.45
Day's Range	6.20 - 6.56
52-Week Range	0.24 - 7.51
Beta	0.73
Analysts	Strong Buy
Price Target	10.25 (+65.06%)
Earnings Date	Mar 19, 2026

About RLMD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Summary

According to 4 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price target is $10.25, which is an increase of 65.06% from the latest price.

Price Target

$10.25

(65.06% upside)

Analyst Consensus: Strong Buy